Publications

The aim of this work is to present the development of a hybrid Brain-Computer Interface (hBCI) which combines existing input devices with a BCI. Thereby, the BCI should be available if the user wishes to extend the types of inputs available to an assistive technology system, but the user can also choose not to use the BCI at all; the BCI is active in the background. The hBCI might decide on the one hand which input channel(s) offer the most reliable signal(s) and switch between input channels to improve information transfer rate, usability, or other factors, or on the other hand fuse various input channels. One major goal therefore is to bring the BCI technology to a level where it can be used in a maximum number of scenarios in a simple way. To achieve this, it is of great importance that the hBCI is able to operate reliably for long periods, recognizing and adapting to changes as it does so. This goal is only possible if many different subsystems in the hBCI can work together. Since one research institute alone cannot provide such different functionality, collaboration between institutes is necessary. To allow for such a collaboration, a new concept and common software framework is introduced. It consists of four interfaces connecting the classical BCI modules: signal acquisition, preprocessing, feature extraction, classification, and the application. But it provides also the concept of fusion and shared control. In a proof of concept, the functionality of the proposed system was demonstrated.

Authors: publisher Tools for brain-computer interaction: A general concept for a hybrid BCI; 2011 Inst Knowledge Discovery; Inst Knowledge Discovery

Journal: cc-by

Published: Kaiser, V; Kreilinger, A; Müller-Putz, GR; Neuper, C;

DOI: true

Abstract ▼

Volume: Müller-Putz||Breitwieser||Cincotti||Leeb||Schreuder||Leotta||Tavella||Bianchi||Kreilinger||Ramsay||Rohm||Sagebaum||Tonin||Neuper||Millán Pages: 104001498||104001498||113876419||105327075||113876419||104001498||103121064||110137930||105327075||113876419||104001498||113876419-gold

Keywords: 2011

AREA MIN. 09 – Ingegneria industriale e dell’informazione – ITA||AUT||ESP

Authors: AREA MIN. 09 - Ingegneria industriale e dell'informazione; ITA; AUT; ESP; title_year; MATCH; 1

Published: Proceedings of the 5th International BCI Conference

AREA MIN. 09 – Ingegneria industriale e dell’informazione – ITA||AUT||CHE||ESP||GBR||GRC

Authors: AREA MIN. 09 - Ingegneria industriale e dell'informazione; ITA; AUT; CHE; ESP; GBR; GRC; title_year; MATCH; 1775143627691; 1

Published: Proceedings of the 5th International BCI Conference

We describe a systematic way of the generalization, to models with nonlinear duality, of the space-time covariant and duality-invariant formulation of duality-symmetric theories in which the covariance of the action is ensured by the presence of a single auxiliary scalar field. It is shown that the duality-symmetric action should be invariant under the two local symmetries characteristic of this approach, which impose constraints on the form of the action similar to those of Gaillard and Zumino and in the noncovariant formalism. We show that the (twisted) self-duality condition obtained from this action upon integrating its equations of motion can always be recast in a manifestly covariant form which is independent of the auxiliary scalar and thus corresponds to the conventional on-shell duality-symmetric covariant description of the same model. Supersymmetrization of this construction is briefly discussed. © 2012 American Physical Society.

Authors: repository Covariant actions for models with nonlinear twisted self-duality; 2012 Dipartimento Fis Galileo Galilei; Sez Padova; Dipartimento Fis Galileo Galilei

Journal: Covariant actions for models with nonlinear twisted self-duality

Published: Pasti, P; Sorokin, D; Tonin, M;

DOI: false

Abstract ▼

Volume: https://arxiv.org/pdf/1205.4243 Pages: 120600194||120600194-green

Keywords: 2012

Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P = 0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P = 0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P = 0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P = 0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).

Authors: publisher N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia; 2012 Populat Hlth Res Inst; Populat Hlth Res Inst

Journal: n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia

Published: Bosch, J; Gerstein, HC; Dagenais, GR; Díaz, R; Dyal, L; Jung, H; Maggiono, AP; Probstfield, J; Ramachandran, A; Riddle, MC; Rydén, LE; Yusuf, S;

DOI: false

Abstract ▼

Volume: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1203859?articleTools=true

Keywords: 2012

5

Authors: publisher Achromic superficial spreading melanoma accidentally treated with imiquimod; 2012 Dermatol Unit; Pathol Unit; Dermatol Unit

Journal: cc-by-nc

Published: Zattra, E; Salmaso, R; Tonin, E; Alaibac, M;

DOI: true

Abstract ▼

Volume: https://medicaljournalssweden.se/actadv/article/download/8797/12278 Pages: 103061702||103061986||103061702-gold

Keywords: 2012

The objective of this study was to describe a large Italian cohort of patients with late-onset glycogen storage disease type 2 (GSDII) at various stages of disease progression and to evaluate the clinical effectiveness of alglucosidase alpha enzyme replacement therapy (ERT). Previous studies showed in late-onset patients ERT efficacy against placebo and variable response in uncontrolled studies. Seventy-four juvenile or adult GSDII patients were treated with ERT in a multicenter open label, non-randomized study, from 12 months up to 54 months. Recombinant human alpha glucosidase (rh-GAA) was injected by intravenous route at 20 mg/kg every second week. Patients were divided into three groups according to ERT duration: Group A received treatment for 12-23 months (n = 16), Group B for 24-35 months (n = 14), and Group C for more than 36 months (n = 44). Clinical assessment included a 6-min walk test (6MWT), forced vital capacity (FVC), the Walton and Gardner-Medwin score, the number of hours of ventilation, body mass index, echocardiography and blood creatine kinase (CK). Included in our cohort were 33 males and 41 females (M:F = 0.8:1), with a mean age at first symptoms of 28.3 years (range 2-55 years) and a mean age of 43 years at study entry (range 7-72 years). Seven wheelchair bound patients, as well as 27 patients requiring ventilation support, were included. After treatment we could observe an increase in distance walked on the 6MWT in the large majority of patients (48/58; 83%), with an overall mean increase of 63 m (from 320 ± 161 to 383 ± 178 m). After treatment in the majority of patients FVC was improved or unchanged (45/69; 65%). In ventilated patients we observed an improvement in average number of hours off the ventilator (from 15.6 to 12.1 h). Six patients stopped mechanical ventilation and two others started it. The effect of therapy was not related to ERT duration. Nine of 64 patients (13%) that underwent to echocardiography showed a variable degree of cardiac hypertrophy (left ventriculum or septum), and a positive effect was observed after 36 months of ERT in one adult case. Discontinuation of treatment occurred in four patients: one drop-off case, one patient died for a sepsis after 34 months of treatment and two patients stopped ERT for worsening of general clinical condition. Mild adverse effects were observed in four cases (5%). This study represents the largest cohort of late-onset GSDII patients treated with ERT, and confirm a positive effect of treatment. These results, obtained in a large case series on therapy, indicate a favourable effect of ERT therapy, even in more advanced stage of the disease. © Springer-Verlag 2011.

Authors: repository Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years; 2012 Dept Neurosci; Dept Neurosci; Dept Neurol Sci; Reg Coordinat Ctr Rare Dis; Dept Neurol; Sect Neuromuscular Dis & Neuropathies; Neurol Unit; Inst Biomed & Mol Immunol; Dept Neurol Sci & Vis; Rare Metab Dis Unit; Immunol & Muscular Pathol Unit; Neuromuscular Unit; Dept Neurosci Psychiat & Anaesthesiol; Neurol Inst; Clin Pediat Neurol; Dept Med Endocrinol Metab & Geriatr

Journal: other-oa

Published: Angelini, C; Semplicini, C; Ravaglia, S; Bembi, B; Servidei, S; Pegoraro, E; Moggio, M; Filosto, M; Sette, E; Crescimanno, G; Tonin, P; Parini, R; Morandi, L; Marrosu, G; Greco, G; Musumeci, O; Di Iorio, G; Siciliano, G; Donati, MA; Carubbi, F; Ermani, M; Mongini, T; Toscano, A;

DOI: false

Abstract ▼

Volume: http://hdl.handle.net/11584/235692 Pages: 113777717||106171087||104623433||113267986||113699233||126351271||104075477||104638897||105514465||103893887||104639508||110467094||113142508||113142508||109503876||104458874||105861393||113953226||113699239||113699239||104623433||113267986||113267986||126351271||105514465||103893887||104639508||110151997||113142508||105861393||104458874||109503876||113953226-green

Keywords: 2012

5

Authors: repository Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years; 2012 Dept Neurosci; Dept Neurosci; Dept Neurol Sci; Reg Coordinat Ctr Rare Dis; Dept Neurol; Sect Neuromuscular Dis & Neuropathies; Neurol Unit; Inst Biomed & Mol Immunol; Dept Neurol Sci & Vis; Rare Metab Dis Unit; Immunol & Muscular Pathol Unit; Neuromuscular Unit; Dept Neurosci Psychiat & Anaesthesiol; Neurol Inst; Clin Pediat Neurol; Dept Med Endocrinol Metab & Geriatr

Journal: other-oa

Published: Angelini, C; Semplicini, C; Ravaglia, S; Bembi, B; Servidei, S; Pegoraro, E; Moggio, M; Filosto, M; Sette, E; Crescimanno, G; Tonin, P; Parini, R; Morandi, L; Marrosu, G; Greco, G; Musumeci, O; Di Iorio, G; Siciliano, G; Donati, MA; Carubbi, F; Ermani, M; Mongini, T; Toscano, A;

DOI: false

Abstract ▼

Volume: http://hdl.handle.net/11584/235692 Pages: 113777717||106171087||104623433||113267986||113699233||126351271||104075477||104638897||105514465||103893887||104639508||110467094||113142508||113142508||109503876||104458874||105861393||113953226||113699239||113699239||104623433||113267986||113267986||126351271||105514465||103893887||104639508||110151997||113142508||105861393||104458874||109503876||113953226-green

Keywords: 2012

5

Authors: publisher A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation; 2012 Dept Pathol; Dept Pathol; Nanotechnol Unit

Journal: A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation

Published: Piccinin, S; Tonin, E; Sessa, S; Demontis, S; Rossi, S; Pecciarini, L; Zanatta, L; Pivetta, F; Grizzo, A; Sonego, M; Rosano, C; Dei Tos, AP; Doglioni, C; Maestro, R;

DOI: false

Abstract ▼

Volume: http://www.cell.com/article/S1535610812003510/pdf Pages: 113059652||132406268||113059652||117667633||113059652||132406268-bronze

Keywords: 2012

Fatigue and exercise intolerance are common symptoms of mitochondrial diseases, but difficult to be clinically assessed. New methods to quantify these rather common complaints are strongly needed in the clinical practice. Coenzyme Q10 administration and aerobic exercise may improve exercise intolerance, but more definite studies are still pending. Herein, we have revised ” how to measure” and ” how to treat” these symptoms of mitochondrial patients. Subsequently, we reviewed the clinical data of the 1164 confirmed mitochondrial patients present in the Italian nation-wide database of mitochondrial disease, with special regard to exercise intolerance. We observed that more of 20% of mitochondrial patients complain of exercise intolerance. This symptom seems to be frequently associated with specific patient groups and/or genotypes. Ragged red fibers and COX-negative fibers are more often present in subjects with exercise intolerance, whereas lactate levels could not predict this symptom. Multicenter efforts are strongly needed for rare disorders such as mitochondrial diseases, and may represent the basis for more rigorous longitudinal studies. © 2012 Elsevier B.V.

Authors: publisher Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases; 2012 Neurol Clin; Neurol Clin; IRCCS Ist Sci Neurol; IRCCS Fdn Ca Granda Osped Maggiore Policlin; Neuropediat & Muscle Disorders Unit; Neuromuscular Unit; Inst Neurol; Dept Neurosci Psychiat & Anaestesiol; Fdn Carlo Besta Inst Neurol

Journal: cc-by-nc-nd

Published: Mancuso, M; Angelini, C; Bertini, E; Carelli, V; Comi, GP; Minetti, C; Moggio, M; Mongini, T; Servidei, S; Tonin, P; Toscano, A; Uziel, G; Zeviani, M; Siciliano, G;

DOI: false

Abstract ▼

Volume: http://www.nmd-journal.com/article/S0960896612006219/pdf Pages: 104458839||112781907||113263640||104534016||113263551||113240986||103645252||110185689||104638385||103618674||106952425||103894101||104458839-hybrid

Keywords: 2012